|
|
Vaccine Detail
|
Tetravalent RNA-lipoplex Cancer Vaccine |
| Vaccine Information |
- Vaccine Name: Tetravalent RNA-lipoplex Cancer Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007112
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- MAGE-1
gene engineering:
- Type: Recombinant protein preparation
- Description: (Sang et al., 2011)
- Detailed Gene Information: Click Here.
- Preparation: RNA-lipoplexes (~ 300–400 nm) were formed by gentle mixing of positively charged liposomes (comprised of DOTMA:DOPE) with the negatively charged gp70 RNA with in a ratio 1.3:2 (Pektor et al., 2018).
- Description: This is for Melanoma Cancer (NCT02410733). A RNA-lipoplex (RNA-LP)-based cancer vaccine containing four naked ribonucleic acid (RNA)-drug products (DPs) RBL001.1, RBL002.2, RBL003.1, and RBL004.1 encoding melanoma-associated antigens (MAAs) encapsulated in liposomes, with potential antineoplastic activity. Upon intravenous administration of the tetravalent RNA-lipoplex cancer vaccine, the liposomes protect the RNA from degradation in the bloodstream, travel to the spleen and are taken up by antigen-presenting cells (APCs); RNA is translocated to the cytoplasm and translated into the four tumor-associated proteins. The expressed proteins are processed and the human leukocyte antigen (HLA)-peptide complexes are presented to the immune system. This induces antigen-specific CD8+ and CD4+ T-cell responses against the four selected MAAs (Sang et al., 2011; NCIT_C122396).
|
| Host Response |
|
|
| References |
NCIT_C122396: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C122396]
NCT02410733: [https://clinicaltrials.gov/ct2/show/NCT02410733]
Pektor et al., 2018: Pektor S, Hilscher L, Walzer KC, Miederer I, Bausbacher N, Loquai C, Schreckenberger M, Sahin U, Diken M, Miederer M. In vivo imaging of the immune response upon systemic RNA cancer vaccination by FDG-PET. EJNMMI research. 2018; 8(1); 80. [PubMed: 30112704].
Sang et al., 2011: Sang M, Wang L, Ding C, Zhou X, Wang B, Wang L, Lian Y, Shan B. Melanoma-associated antigen genes - an update. Cancer letters. 2011; 302(2); 85-90. [PubMed: 21093980].
|
|
